Newest long-lasting frown line treatment at ZO Skin Centre Dallas

Article metadescription etiam eu condimentum arcu, a tincidunt diam. Maecenas lacinia, lectus in bibendum mollis, nulla massa finibus turpis, vel iaculis ex erat et leo. Phasellus nisi libero, tempor a sagittis nec, varius quis.

Newest long-lasting frown line treatment at ZO Skin Centre Dallas

Newest long-lasting frown line treatment at ZO Skin Centre Dallas

What is Daxxify?

Daxxify is a FDA approved, long-lasting neuromodulator indicated for temporary improvement of moderate to severe glabellar (frown) lines.

Daxxify is the only long-lasting peptide-powered forwn line treatment stabilized with Peptide Exchange Technology™ (PXT) which lasts on average 6 to 9 months where as conventional neuromodulators such as Botox usually last 3 to 4 months.

A look that lasts

According to Revance Aesthetics’ clinical trials, at least 50% of patients had no minor frown lines 6 months after treatment. Between 3% and 5% of patients in clinical studies had no or minor frown lines 9 months after treatment.

In other safety studies, between 5% and 17% of patients had noticeable improvement 9 months after.

Why ZO Skin Centre Dallas loves Daxxify

Nurse Practitioner Jessica Orman said that patients love Daxxify because it means less in-office visits, making it more cost effective and budget friendly. Rather than getting Botox every 3 to 4 months, Daxxify patients are coming in twice a year for long lasting results.

"The main reason I love it is because it helps prevent resistance," Jessica said. "If you're an avid Botox user and it isn't lasting as long, Daxxify can be used in rotation so your body doesn't adapt to it."

Learn about Kyli’s experience with Daxxify at ZO Skin Centre Dallas:

The long-lasting results you've been waiting for

Want more time with less lines? Ask for Daxxify by name today at ZO Skin Centre Dallas.

* All information subject to change. Images may contain models. Individual results are not guaranteed and may vary.


Get updates to the latest news